ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
Ana Portelinha, Scott K. Thompson, Roger A. Smith, Mariana Da Silva Ferreira, Zahra Asgari, Andrea Knežević, Venkatraman Seshan, Elisa de Stanchina, Sandeep Gupta, Louis Denis, Anas Younes, Sanjeeva Reddy
Abstract
due to dual inhibition of RAS/MAPK and PI3K survival pathways. Our data provide a rationale for evaluating ASN007 in RAS/RAF-driven tumors as well as a mechanistic basis for combining ASN007 with PI3K inhibitors.
Topics & Concepts
HRASNeuroblastoma RAS viral oncogene homologKRASMAPK/ERK pathwayCancer researchKinaseMEK inhibitorMelanomaPI3K/AKT/mTOR pathwayIn vivoMutantChemistryBiologySignal transductionMutationBiochemistryGeneBiotechnologyMelanoma and MAPK PathwaysCancer Mechanisms and TherapyCytokine Signaling Pathways and Interactions